Dextromethorphan as an Early Post-Trauma Prophylactic Candidate: Mechanistic Basis and Translational Challenges
Nathaniel Martin preprint
A disease-first off-patent drug-repurposing engine identified dextromethorphan (DXM) as a compound that could lower the risk of post-traumatic stress disorder (PTSD) when administered soon after exposure to severe stress. DXM combines anti-inflammatory activity, N-methyl-D-aspartate (NMDA) receptor antagonism, sigma-1 receptor agonism, and monoamine re-uptake inhibition, a profile that targets...